Skip to main content
. 2020 Apr 16;38(17):1928–1937. doi: 10.1200/JCO.19.02515

FIG 2.

FIG 2.

Response rates to lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy (evaluable patients, n = 977). ASCT, autologous stem-cell transplantation; CR, complete response; ORR, overall response rate; PD, progressive disease; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response. (a) Seven hundred forty-two evaluable patients of 751 patients who underwent up-front transplantation.